Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Paul Duff

Physician Assistant, Medical Jacksonville, FL Physician Assistant

NPI 1821092503 CMS profile 11015309

2700 Riverside Ave, Ste 2, Jacksonville, FL 32205

Open in the dashboard

General payments

$35,230

503 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$140 paid to institutions, not to them · program year 2023

Through program year 2025, Paul Duff of Jacksonville, FL is reported in the CMS Open Payments database as having received $35,230 across 503 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $140 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,866 111
2024 General $9,701 114
2023 General $6,348 85
2022 General $4,085 99
2021 General $4,230 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Duff
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Paul Duff were reported at $10,866. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Paul Duff Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,230 $156 $41–$563 $132
2022 $4,085 $185 $55–$649 $149
2023 $6,348 $199 $58–$717 $160
2024 $9,701 $206 $62–$740 $164
2025 $10,866 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $26,226 149 payments
  2. AbbVie, Inc. $1,496 86 payments
  3. Boston Scientific Corporation $1,152 23 payments
  4. Abbott Laboratories $969 27 payments
  5. Amgen Inc. $553 25 payments
  6. TerSera Therapeutics LLC $513 24 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $460 28 payments
  8. Spinal Simplicity, LLC $403 4 payments
  9. SPR Therapeutics, Inc $332 7 payments
  10. Ferring Pharmaceuticals Inc. $254 13 payments
  11. Other $2,872 117 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,046 459 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,776 10 payments
  3. Travel and Lodging $6,408 34 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $16,318 61 payments
  2. INTELLIS ADAPTIVESTIM $6,656 68 payments
  3. RESTORE $1,920 1 payment
  4. UBRELVY $792 53 payments
  5. QULIPTA $778 48 payments
  6. INCEPTIV $708 10 payments
  7. RELISTOR $444 27 payments
  8. Prialt $406 19 payments
  9. HA MINUTEMAN G3-R $403 4 payments
  10. WaveWriter Alpha Prime 16 $372 5 payments
  11. Other $7,146 266 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,714

Median for Physician Assistant: 241

Drug cost

$92,957

Median for Physician Assistant: $4,110

Branded share of claims

3.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 22 $33,385
Movantik Naloxegol Oxalate Brand 29 $13,483
Lidocaine Generic 81 $11,900
Emgality Syringe Galcanezumab-Gnlm Brand 13 $9,238
Gabapentin Generic 455 $6,589
Tizanidine Hcl Generic 319 $5,417
Diclofenac Sodium Generic 85 $3,220
Baclofen Generic 91 $1,870
Cyclobenzaprine Hcl Generic 112 $1,764
Methocarbamol Generic 114 $1,604

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$116,653

Medicare's payments for the services billed

Medicare patients

236

Average age 71

Services billed

1,116

140 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 45%
Diabetes 42%
Ischemic heart disease 35%
Chronic kidney disease 31%
COPD 29%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $158
$158 — —
Prialt
  • TerSera Therapeutics LLC $143
$143 — —
BOTOX
  • AbbVie, Inc. $142
$142 — —
KRYSTEXXA
  • Amgen Inc. $117
$117 — —
UBRELVY
  • AbbVie, Inc. $96
$96 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

503 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record